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Abstract. Blastocystis hominis (B. hominis) is an anaerobic, single-cell protozoan, commonly present in human and animal 
stool samples. It can be found in healthy people as well and it still has not been elucidated whether it is a commensal 
organism or a pathogen. Blastocystosis is a disease caused by the protozoan in humans. The prevalence of the parasitosis 
varies both between the countries, and between certain population groups within individual countries. Due to poor hygienic 
conditions, common exposure to animals and intake of contaminated water and food, people in the developing countries 
have got a higher prevalence of blastocystosis, but economically developed countries have not been spared either. The 
taxonomy of B. hominis is still a matter of debates. For the reasons of genetic diversity, it has been suggested that the name 
B. hominis should be replaced with „Blastocystis species‟. Seventeen subtypes of the species have been so far identified, and 
a definitive characterization of Blastocystis spp. is possible at the molecular level only. The parasite is transferred by the 
fecal-oral route. A variety of hosts have been identified, and animal-to-human and vice versa transfers have been 
documented. The most common manifestations of the infection with the organism are diarrhea, abdominal pain, nausea, and 
bloating. This infection has also been associated with the irritable bowel syndrome (IBS), non-specific colitis, chronic 
inflammatory bowel disease (CIBD), and urticaria. The diagnosis can be made using the methods of conventional 
microscopy (CVM), phase-contrast and electron microscopy, cultivation, serodiagnosis, and by using molecular methods. 
The infection caused by the parasite does not always require treatment. In symptomatic patients, the first line medical 
treatment is metronidazole. Further studies are required to resolve all dilemmas regarding the parasite. 
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Introduction 

 
Blastocystis hominis (B. hominis) is an ubiquitous parasite 
spread widely in the tropical climate areas. It is commonly 
present in human and animal stool specimens (in birds, 
rodents, reptiles, amphibians, fish, cockroaches). Its role as 
the cause of an infection has not been fully elucidated. 
Throughout the literature, the organism has been reported 
as a commensal organism, but also as a pathogen. In recent 
years, numerous studies have been published reporting 
that the infection with B. hominis is common in immuno-
compromised individuals [1,2]. 
The organism belongs to single cell, anaerobic 
eukaryotes (protists). Brittain and Swayne, independently 
of each other, detected the microorganisms studying a 
cholera epidemic in London in 1849, wrongly identifying 
them as the cause of cholera [3]. Blastocystis, the name of 
the genus, was given by Alexeieff in 1911, and the fol-
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lowing year the name of the species was suggested by 
Emile Brumpt [4]. Zierdt et al. performed a reclassification 
and classified the organism among protists, based on its 
morphological and phenotypic characteristics (one or 
several nuclei, cellular organelles similar to mitochondria, 
endoplasmatic reticulum and Golgi apparatus, inability to 
grow on fungal culture media, resistance to antifungal 
agents, and sensitivity to antiprotozoal drugs) [5]. 
Classification 
At the end of the XX century, Silberman et al. classified 
the organism among eukaryotes, of the Heterokontophyta 
type, based on the molecular analyses of small subunit 
(SSU) rRNA (SSU-rRNA) and elongation factor 1 (EF-
1α) [6]. Although the taxonomy such as this was 
controversial when related to other studies demonstrating 
a similarity of Blastocystis spp. parasite with protists, 
the subsequent studies confirmed the assertion presented 
above [7, 8]. There are over 100.000 members of the 
Heterokontophyta order, commonly termed heterokonts 
or stramenopiles, and Blastocystis spp. becomes a new 
member of the complex group of the so-called „botanical 
protists“ [9,10]. By way of phylogenetic analysis of 
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SSUrRNA and HSP70c, a close connection between 
Blastocystis spp. parasite and stramenopiles has been 
confirmed, in spite of its absence of flagella and tubular 
elongations [9]. Despite the classification at a molecular 
level, there is a difference in morphology between 
blystocystis and other stramenopiles (flagella surrounded 
by lateral hairlike mastigonemes) [11,12]. 
The origin of the organism at the species level has 
not yet been resolved. There are several host-specific 
species: B. hominis in people, and B. ratti in rats [13]. 
Host diversity is well known, and human-to-animal and 
vice versa transfer is well documented [14]. In humans, 
any of the isolated species is termed B. hominis [4], 
although, due to its genetic diversity, the suggestions 
have been put forward that the term B. hominis should 
be replaced with Blastocystis species [13]. 
Because of all these facts, a step towards classification 
of different species has been made based on their ultra-
structural morphological characteristics visualized by way 
of electron microscopy [15]. Host specificity and patho-
genic potential of different isolates correlate with sequence 
variations in SSU-rRNA [14]. Conserved and variable 
regions within 18 SSU-rDNAs constitute the basis for 
identification of phylogenetic relations between the spe-
cies [13]. Moreover, rRNAs are made use of in diag-
nostic PCR analyses with high sensitivity [16]. A recent 
genetic classification of B. hominis into subtypes (STs) 
is the equivalent to earlier species classification [13]. 
SSU-rDNAs correlate with subtypes and 17 have been 
reported so far, so that definitive characterization of 
species is possible at a molecular level only [13]. 
Host-specificity is determined by STs, where ST1 
and ST8 colonize/infect humans (not only them, how-
ever, but other hosts as well) [13]. ST9 has been found 
only in humans, while ST10-17 are present in other 
hosts as well [14,15].  
Biology and Morphology 
B. hominis is a strict anaerob with observed intacellular 
structures similar to mitochondria, but lacking cytochrome 
enzymes. Intracellular organelles are involved in different 
metabolic pathways (metabolism of amino acids, biogene-
sis of iron and sulphur, and tricarboxylic acid cycle). 
The organism is able to synthesize certain essential cel-
lular phospholipids and to accumulate them most com-
monly within the storage vacuoles [3]. The average 
generation time of Blastocystis species is 1722 h, alt-
hough it depends on the medium used for cultivation. 
Generation time differs among different STs [17]. The 
microorganism enters apoptosis after exposure to harsh 
conditions (exposure to room temperature, air, or an-
tiparasitic agents such as metronidazole). The phenom-
enon serves as a mechanism aimed to increase the 
number of viable cells in such conditions [18]. 
B. hominis has got several different morphological 
forms. Vacuolar, granular, ameboid, and cystic forms 
are the ones best described so far. Other morphological 
forms have also been found on electron microscopy 
(avacuolar and multivacuolar, of small dimensions and 
rarely present). In fresh stool samples and culture sam-
ples, vacuolar and granular forms are the ones most 
commonly encountered; they can be visualized using 
phase-contrast microscopy, with light microscopy of 
native and stained sample preparations and with electron 
microscopy [4]. 
Vacuolar form. This form of B. hominis is spherical, 
containing a central body representing a large vacuole, 
occupying approximately 90% of the cell, and a thin layer 
of peripheral cytoplasm situated immediately beneath the 
cell membrane. The nuclei can be distributed peripherally 
throughout the cytoplasm. There can be seven nuclei at 
the most, but there are two nuclei on the average, situated 
at the opposite ends of the cell [19]. Mitochondrion-re-
lated organelles and Golgi apparatus are located peripher-
ally in the cytoplasm. Mitochondria look like roses 
placed around the nucleus. These structures may pro-
trude within the central body and can have a fiberlike 
appearance [13]. It has been discovered that the central 
body is a membrane-enclosed vacuole, containing car-
bohydrates, fats, and basic proteins. These substances 
are accumulated within the vacuole by way of the action 
of the Golgi apparatus and via clathrin-mediated endo-
cytosis [20]. The body most probably has storage and 
apoptosis-related roles [3,9]. Vacuolar forms can be of 
different sizes (ranging from 3 µm to 120 µm), but meas-
uring 5 µm to 15 µm on the average [13]. It is generally 
accepted that this form is most commonly seen in 
asymptomatic carriers of B. hominis [1]. 
Granular form. This form is very similar to vacuolar 
forms of B. hominis, but contains the granules within the 
cytoplasm which are often centrally situated. In 1989, 
Dunn et al. proposed that these structures were similar to 
myelin-like inclusions, small vesicles, crystal granules, and 
drops of fat. The granules can be metabolic, reproductive, 
and lipid ones [13]. It is possible that reproductive granules 
have a role in schizogony. On the average, there are two 
nuclei in the cytoplasm (four at the most). They have a 
slightly smaller diameter compared to vacuolar forms, 
and measure 9.0 μm to 28.3 μm [19]. They are more 
frequent in older cultures and the cultures treated with 
antibiotics, and there has also been the hypothesis that 
their existence is an indicant of cell death [1]. 
Ameboid form. This form of B. hominis is most 
rarely encountered. It is irregular in shape, with 12 
pseudopodia (being stationary nevertheless), with con-
siderable adhesion abilities, enabling its attachment to 
the bowel mucosa [1]. There is a large vacuole in its 
cytoplasm, and this form is in fact transformed into 
cystic form. Since they resemble neutrophils and mac-
rophages, they can easily escape recognition on routine 
stool sample examinations. Zierdt has suggested Gram 
staining of unfixed smears to be undertaken for their 
identification, since these forms undergo lysis when 
exposed to air, while leukocytes remain intact [4,9]. It is 
more commonly present in individuals with symptoms 
of digestive tract infections and in cultures, indicating 
the pathogenic potential of this form of B. hominis [1,21]. 
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Cystic form. These are round or oval, and with 
smaller dimensions (36 μm) [13]. These forms found in 
certain animals are larger [15]. Cystic forms have a thin, 
multilayered wall with/without a surface envelope [19]. 
Their condensed cytoplasm has got several mitochondria 
and storage vacuoles. The number of nuclei within the 
cysts varies from 1 to 4. A cyst may survive about a 
month exposed to air and the temperature of 25°C and 
enables further spread of the infection – it is a form infec-
tious for humans [1,9]. 
Vegetative forms are transformed into other vegetative 
forms with different morphology and can thus escape 
identification in stool samples [3]. Avacuolar and multi-
vacuolar forms are the most dominant forms in vivo, and 
these also most commonly remain unrecognized on mi-
croscopy [22]. 
Life cycle 
Infectious, cystic forms of B. hominis are transmitted by 
the fecal-oral route [23]. The infection may occur after 
an intake of untreated water or uncooked water plants 
contaminated with cysts, and also via dirty hands [24, 
25]. In an adequate host, the cyst develops via the pro-
cess of excitation into vegetative forms within the large 
bowel [9]. 
Further continuation of the life cycle depends on the 
subtype compatibility with the host [13]. Other forms 
can also develop from vacuolar ones. After a period of 
time after the infection, vacuolar forms form the cysts in 
the bowel lumen [22]. The encystation occurs during the 
passage through the large bowel, and the cysts are then 
excreted via feces. Fecal cysts can be covered with a 
fiber-like layer which gradually disappears during the 
cyst development. A thin fibrillar surface layer detected 
in stool samples plays a significant role in the survival 
of this parasite in vivo [22]. 
It is thought that different modes of reproduction 
exist when this organism is concerned (binary fission, 
budding, plasmotomy, multiple fission, endodyogeny, 
schizogony). Binary fission is nevertheless the most 
common mode [26]. 
Virulence 
The studies conducted to establish the pathogenicity of 
B. hominis parasite have been so far unconvincing and 
disputable. There are some acceptable explanations of 
pathogenicity related to the species STs and virulence 
(27, 28). Symptomatic patients are usually infected with 
ST1 - 4, and 6 (with ST3 being the most common, fol-
lowed by ST1 and ST2). Subtype-related variations in 
pathogenicity have been observed as well, which probably 
can explain the differences between the patogenic and 
non-pathogenic potentials of the species. 
Ameboid B. hominis form, which excretes proteases, 
is the most virulent one. It is predominant in symptomatic 
patients and these forms should be sought in stool speci-
mens in patient screenings [22,2830]. In addition to 
proteases, other hydrolytic enzymes have been identified 
as well by way of electrophoresis. Lysates lead to cyto-
skeletal changes and induce apoptosis in epithelial cells, 
which results in increased bowel permeability. Cystein 
proteases stimulate mucosal cells to produce interleukin-
8. This mechanism is responsible for the loss of fluids 
and bowel inflammation in the affected. Proteases cleave 
secretory IgA and help in immune evasion and survival 
of the parasite [3,31]. 
Whole-genome sequencing has been done for ST7. The 
genes have been identified which code the proteins that 
alter bowel homeostasis. The genes responsible for the 
production of nonribosomal peptides and polyketides (an-
tibacterial and inducing bowel dysbiosis) have also been 
identified. The target genes coding for hydrolases have 
been also described (capable of altering the bowel mucous 
layer and exposing the epithelium for parasite adhesion). 
Expression of serine proteases and glycosyltransferases 
disturbs the firm bonds in the bowel mucose epithelium, 
leading to increased bowel permeability [3,32]. 
The molecules responsible for extraintestinal mani-
festations of the infection are relatively unknown. B. 
hominis antigens stimulate T-helper II cells, leading to 
an IgE-mediated allergic reaction. The organism proba-
bly activates the complement cascade, which leads to 
the release of anaphylatoxin and mast cell activation. 
Iron deficiency anemia associated with B. hominis infec-
tion is still awaiting explanation [33,34]. In general, viru-
lent strains are larger, with an uneven, rough surface, they 
grow slowly and demonstrate an increased affinity to 
bind to lectins. 
The relationship between the severity of infection 
and clinical manifestations is still unclear [3538]. One 
study has proposed that 32kDa proteases of ST3 could 
be the virulent factors responsible for protein degradation, 
while another study has found that a B. hominis 29 kDa 
antigen could be used as a pathogenicity marker, enabling 
differentiation of symptomatic from asymptomatic B. 
hominis infections [39,40]. Increased IgA levels have 
been described in symptomatic individuals with B. homi-
nis infection, compared to healthy asymptomatic carriers 
of B. hominis [41]. 
A recent study about the impact of B. hominis para-
site on the expression of gamma interferon and proin-
flammatory cytokines of the cecal mucosa in rats has 
shown a significant upregulated transcription of type 1 
gene and proinflammatory cytokines IFN-gamma, IL-12, 
and TNF-α. This suggests that B. hominis infection in rats 
stimulates specific local host responses, involving T cells, 
monocytes, macrophages, or natural killer cells [42]. 
Studies on mice inoculated with high doses of Blasto-
cystis spp. have shown a loss of weight in mice and onset 
of diarrhea [4345]. Studies have also demonstrated that 
Blastocystis spp. can attack the lamina propria, submu-
cose, and muscle layers, and to invade the epithelium of 
the rat colon in view of the increased levels of hyalu-
ronidase in the urine of rats infected with Blastocystis 
spp., which stil is not a sufficient proof of similar events 
in people [46,47]. Laboratory rats constitute a good model 
of the pathogenesis of Blastocystis spp. infection, in con-
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trast to mice which have not been naturally infected with 
Blastocystis spp. [48]. 
There have been several reports suggesting that 
Blastocystis spp. could be associated with urticarias in 
humans [9]. Ameboid forms of ST3 Blastocystis spp. 
have been identified in the cases of acute urticaria, and 
authors believe that cutaneous symptoms can be caused 
by a disruption in the immune homeostasis [49]. In an-
other study, Blastocystis spp. ST2 has been demon-
strated in a patient with severe gastrointestinal com-
plaints and chronic urticaria, in absence of any other 
infectious agent. The complaints persisted after the ini-
tial antibiotic therapy, but were eliminated after com-
bined metronidazole and paromomycin therapy [50]. 
Clinical Significance and Treatment 
In view of the controversies related to the pathogenicity 
of B. hominis in humans, the results of numerous studies 
confirmed/excluded B. hominis as a disease cause. In 
certain studies, the individuals susceptible to an infec-
tion with the parasite have been mentioned: HIV in-
fected individuals, patients with cancer or with other 
immune difficiency conditions, children from the devel-
oping countries, frequent travellers [13]. 
It seems that clinical manifestations of blastocystosis 
depend on the subtype of the parasite. ST1 subtype has 
been found in those with symptoms of the infection 
[51], while in Columbia it has been documented in 
asymptomatic examinees [52]. B. hominis of ST2 has 
got a controversial pathogenicity, positively demonstrated 
in some studies [5254], and disputed in the others [55,56]. 
Regarding the most common B. hominis subtype ST3 iso-
lated in humans, there have been little evidence that 
could indicate its pathogenicity. Around 40% of those 
infected with ST4 of B. hominis have got gastrointestinal 
symptoms, found as well in those with the clinical picture 
of severe diarrhea [57,58]; ST5 subtype has been found in 
those with symptoms of the infection [59], in those coming 
into contact with animals and in animals themselves 
[60,61]. B. hominis subtype ST6 causes diarrhea in a 
third of the infected, and B. hominis subtype ST7 is also 
associated with the onset of diarrhea [57]. 
Clinical characteristics of the disease are non-specific 
and consist of abdominal pain, acute/chronic diarrhea, nau-
sea, anorexia, bloating, perianal itching (abdominal pain 
and diarrhea being the most common complaints). The 
symptoms range from mild and moderate, to severe acute 
and chronic events. The number of parasites found in stool 
specimens determines the severity of symptoms and signs 
of the infection [1,9,22,37,38]. 
B. hominis is associated with the irritable bowel syn-
drome (IBS), since the changes in the intestine occur  
(caused by this disorder) that favor the development of the  
parasite [13]. It is believed that low-intensity inflammation 
occurs as the consequence of constant immune activation 
caused by the parasite and persistent antigen exposure of 
the host [62]. Moreover, increased levels of IgG2 immu-
noglobuline against B. hominis have been found in the 
examinees with IBS [63]. Blastocystosis has been associ-
ated with non-specific colitis too, as well as with chronic 
inflammatory bowel disease (HIBD) (including Crohn’s 
disease and ulcerous colitis) [14,64,65]. 
Eosinophilia and skin changes (primarily urticaria) 
are rarely encountered in patients [9,13]. There have been 
several individual cases of B. hominis infection in pa-
tients with chronic kidney disease [66,67] and arthritis 
[66, 68-71). A high prevalence of the infection (95.8%) 
has been described in immunocompromised patients 
(HIV positive individuals and those with AIDS) [72]. 
However, not all of the infected develop symptoms and 
signs of the disease. These are asymptomatic individuals – 
there are many more asymptomatic cases than those with 
symptomatic B. hominis infection [27,30,41,56,64]. 
There is also the question whether the infection with 
this parasite requires treatment. In symptomatic patients 
with confirmed infection (the finding of B. hominis in 
the stool specimen), it is necessary to examine the pres-
ence of other infective agents in the gastrointestinal 
tract, since there is a real possibility of coinfection with 
other pathogens as well [13]. 
Metronidazole is a first choice drug in cases of 
proven infection. It’s effectiveness, however, has been 
known to vary. It is effective in some patients, but it 
cannot produce complete eradication of the infection 
(especially a severe one). There is a possibility that non-
responders have been infected with resistant B. hominis 
subtypes. The studies dealing with metronidazole effi-
cacy have not elucidated the association between B. 
hominis subtypes and treatment failure [13]. 
Trimethoprim – sulfamethoxazole is the second choice 
drug for those who failed to respond to metronidazole 
treatment. It has been demonstrated that paromomycin, a 
wide spectrum antibiotic indicated in acute and chronic 
intestinal amebiasis, is successful as the treatment of 
Blastocystis infections associated with skin lesions (pre-
dominantly urticaria) [7376]. 
Yakoob et al. have studied the efficacy of garlic and 
other dietary herbs in vitro in comparison with metronida-
zole in individuals infected with B. hominis. The authors 
assessed the efficacy of garlic and metronidazole in con-
centrations of 0.01 and 0.1 mg/ml. They found that garlic 
and metronidazole were equally effective in both concen-
trations. Blastocystis isolates were not sensitive to other 
tested herbs such as ginger, black pepper, and white cumin 
[77]. It has been established that probiotics such as Saccha-
romices boulardii are equally effective as a symptomatic 
treatment as metronidazole [13,78].  
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Diagnosis 
Conventional microscopy of (CVM) 
(with/without concentration method): 
 native preparations (unstained/Lugol stained). If 
Lugol’s solution is added, parasites are stained golden 
yellow. However, due to Blastocystis polymorphic 
structure, a wrong identification can occur and their 
misinterpretation as fungi, Cyclospora spp., and drops 
of fat [13]. Classical vacuolar forms do not have to be 
predominant in fresh stool sample, while smaller forms 
can be hard to identify [60]. For the diagnosis of 
Blastocystis infection to be made, several stool sam-
ples (at least 3) are required, more than 5 cysts in 
the visual field without other parasites [1]. 
 stained preparations (by Giemsa, Gram, Wright, iron 
hematoxylin) [80]. A common staining in the diagnosis 
of Blastocystis is trichrome staining. With this 
method, the large central body is usually stained green 
to gray. Inclusion bodies in the cytoplasm stain light to 
dark red. 
Phase-contrast microscopy 
Phase-contrast microscopy is more convenient than light 
field microscopy when greater magnifications are re-
quired and when samples are colorless or their details are 
so minute that color cannot be discerned well [80]. Phase-
contrast microscopy enables the study of morphological 
features of the cells and of their reproduction via cell divi-
sion. 
The fundamental principle of phase change visuali-
zation in phase-contrast microscopy is the separation of 
background light from the specimen-scattered light, which 
enables better visualization (highlighting) of the required 
image details; the phenomenon is based on the property of 
cells to have a refractive index different than that of the 
surrounding medium [9]. 
Transmission electron microscopy (TEM) 
In the routine diagnosis of Blastocystis TEM is not 
used; it is used however in the demonstration of atypical 
forms of the parasite [9]. 
Cultivation 
When CVM specimens are positive to the vacuolar 
forms of B. hominis, cultivation on the Löwenstein-
Jensen (LJ) medium is performed: a 48-hour incubation 
in anaerobic conditions, when white, very bright and 
mucous colonies grow [81]. A native preparation with 
physiological solution is made of the suspect colonies 
and is inspected microscopically, when vacuolar forms 
of B. hominis are seen [82]. 
Xenic and monoxenic laboratory cultures of B. hominis 
isolates, growing together with non-standardized or indi-
vidual known types of microorganisms, can be kept alive 
in the Jones’ or Boeck-Drbohlav condensed medium 
[83,84]. The Jones’ medium is the medium of choice for 
the studies involving cultures for parasite identification 
from patient specimens [81,8588]. 
Axenic cultures, i.e. the cultures without any other 
living organism(s), demonstrate a rich growth in differ-
ent media [89,90]. B. hominis cells can grow on a solid 
medium as well, and its colonies macroscopically ap-
pear similar to bacterial colonies [91]. The colonies may 
survive up to 2 weeks and can be preseeded in a liquid 
or solid medium [92]. It is interesting that the same iso-
lates cultured in a liquid medium reach their maximum 
cell density around day 4 after inoculation, and enter the 
dying phase on day 5, so that the growth of their sub-
cultures is made difficult [9]. This indicates that growth 
characteristics of the same isolates in a solid medium 
are essentially different from the characteristics of 
Blastocystis isolates grown in a liquid medium. 
Axenic cultures of Blastocystis isolates are very im-
portant for molecular and biochemical research. Axeni-
zation can be accomplished by the addition of antibiotic 
cocktails in order to eliminate bacteria and fungi. Several 
combinations of antibiotics have been so far described, 
used with variable success. The procedure is generally a 
demanding one, lasting for weeks or months, without any 
guarantee that the bacterial contaminants would be elimi-
nated in the end. It has been supposed that some of the 
isolates require the presence of bacteria for their survival, 
so that the removal of all bacteria can result in the death 
of the parasite [9]. 
Lanuza et al. have improved the method for Blasto-
cystis spp. axenization and succeeded to axenize 25 out of 
81 isolates. The time required for axenization was about 3 
weeks [93]. In addition to an antibiotic treatment, some 
authors have pointed out that physical methods can con-
tribute to the success of axenization – separation of para-
sites from the mass of sprouting bacteria [9396]. 
Serodiagnosis 
The infections caused by B. hominis lead to IgA and IgG 
immune response, and antibodies can be demonstrated 
using indirect immunofluorescent (IFA) and enzyme-
linked immunosorbent assay (ELISA) tests [97]. 
An IFA assay involves a highly specific and sensitive 
method for the confirmation of B. hominis parasite. Com-
mercially available immunofluorescent antibodies are 
used, specific for B. hominis. Based on polyclonal anti-
bodies, the subtypes of B. hominis ST1-ST3 and ST5 
can be determined using the ELISA test [97]. 
Symptomatic infections are associated with elevated 
IgG antibody titer. In asymptomatic infections, IgA re-
sponse is weak or absent. The strongest immune response 
is reported for chronic infections. Since the knowledge 
concerning host immune response to B. hominis infection 
is still limited, and since antigen diversity of the parasite is 
obvious, serologic tests are not routinely used, but their use 
is of key importance in epidemiological and other scientific 
research. These methods are far more sensitive and specific 
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than CM and the tests are nowadays commercially availa-
ble [9,97]. 
Molecular methods 
Amplification of B. hominis DNA obtained from fresh 
stool samples or from culture is convenient for the pur-
pose of epidemiological and screening studies, and gen-
otyping should be included in the analysis as well [9]. 
The development of a real time polymerase chain reac-
tion (PCR) method for sufficiently sensitive and rapid 
detection of Blastocistis spp. and the ability to differen-
tiate between the genotypes present in the specimen 
would be equally useful in screening and in epidemio-
logical studies [9]. 
Epidemiology 
B. hominis is a ubiquitous parasite. Its prevalence varies 
between the countries and from one population group 
to another. People in the developing countries have got 
a higher prevalence of blastocystosis due to poor hy-
gienic conditions and intake of contaminated water and 
food [51]. 
However, B. hominis has got a wide geographical 
distribution and can be found in economically developed 
countries as well [97,98]. A study involving the whole 
territory of the USA, conducted by the Center for Disease 
Control and Prevention and using the 1987 data, reports 
the prevalence of B. hominis infection of 2.6% in the 
general population [99], while a study published in 
2000, performed in private laboratories in 48 states of 
the USA, shows the prevalence of blastocystosis of 23% 
[100]. In Canada, B. hominis was the most common 
cause of protozoal infections in 2005 (101). 
B. hominis was the parasite most commonly isolated 
in Indonesia, in the HIV infected and those with AIDS 
tested before the administration of antiretroviral therapy 
[102] and in Turkey in cancer patients [103]. An increased 
prevalence of the parasite in individuals in contact with 
animals suggests the possibility of a zoonosis [27]. 
The distribution of genotypes established using the 
PCR method has been reported in several countries: 
Bangladesh, Germany, Pakistan, Japan, Singapore, 
Greece, Turkey, China. The ST3 subtype established in 
China is the most predominant one, while ST1 has been 
found in a lesser degree in Singapore, Greece, and Ger-
many [13]. There are also mixed type infections with 
different subtypes, most commonly with ST1 and ST3 
[51,55,104,105]. 
A recent study in our country has shown that children 
with blastocystosis have colitis as the most common large 
bowel pathology, without any significant difference be-
tween non-specific colitis and HIBD. The infection is most 
commonly found in children aged 2 to 3 years, followed by 
those 16 to 18 years of age. Significantly higher number of 
the infected live in houses compared to flats, and possess 
domestic animals and/or pets. A positive fecal occult blood 
test, iron-deficiency anemia, elevated erythrocyte sedi-
mentation and CRP are characteristic of those with B. 
hominis infection and HIBD who have a larger number of 
parasites in their stool samples. Mesenteric lymphadenitis 
and splenomegaly are the most commonly described path-
ologic changes on the abdominal ultrasound of children 
infected with B. hominis hospitalized for the complaints 
of abdominal pain and/or diarrhea. The author concludes 
that the establishment of a pathogenic significance of B. 
hominis contributes to the recognition of this protozoan 
as a pathogen and stresses the necessity of a treatment 
for the condition [106]. 
The first studies in the region of Niš concerning the 
prevalence of blastocystosis in patients with/without 
infection symptoms have been published about a decade 
ago; the prevalence of 4.05% was then established among 
the healthy, and 0.36% among those with symptoms of the 
infection [107]. Based on still unpublished data of the Par-
asitology Laboratory, Public Health Institute, the total 
prevalence of B. hominis has been reduced in the last 
decade (2.7%) in asymptomatic individuals. 
Conclusion 
Blastocystis hominis is still a mysterious and perhaps 
scientifically disregarded parasite in human pathology. 
Differentiation among Blastocystis species is not possible 
using the routine methods. The use of DNA methods ena-
bles detection of genetic variations in these parasites with 
still uncertain taxonomy. Epidemiological molecular stud-
ies are especially useful in the establishment of transmis-
sion patterns, host specificity, and in the surveillance of 
chemotherapeutic resistance. 
Distribution and genotypic diversity of Blastocistis spp. 
have not been studied so far in Serbia, which necessitates a 
systematic research of the parasite and filling in of the epi-
demiological map, as well as the establishment of signifi-
cance of the organism in  human pathology. 
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